Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 10/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.47 |
| ▸ | USP2 | O75604 | 7/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2656183 | 0.79 | CYP2D6 (0.55) | CYP3A4CYP2D6USP2CYP2C9CYP1A2 | |
| SCHEMBL5527398 | 0.79 | OPRL1 (0.49) | CYP3A4CYP2D6USP2CYP2C9CYP1A2 | |
| SCHEMBL9230667 | 0.79 | CYP2D6 (0.47) | CYP3A4CYP2D6USP2CYP2C9CYP1A2 | |
| SCHEMBL5455644 | 0.79 | NPSR1 (0.53) | CYP3A4CYP2D6USP2CYP2C9CYP1A2 | |
| SCHEMBL4840431 | 0.76 | NPSR1 (0.46) | CYP3A4CYP2D6USP2CYP2C9CYP1A2 | |
| SCHEMBL4841029 | 0.75 | NPSR1 (0.45) | CYP3A4CYP2D6USP2CYP2C9CYP1A2 | |
| SCHEMBL5457749 | 0.75 | NPSR1 (0.45) | CYP3A4CYP2D6USP2CYP2C9CYP1A2 | |
| SCHEMBL14742155 | 0.74 | CYP3A4 (0.69) | CYP3A4CYP2D6USP2CYP2C9CYP1A2 | |
| SCHEMBL4837814 | 0.73 | NPSR1 (0.44) | CYP3A4CYP2D6USP2CYP2C9CYP1A2 | |
| SCHEMBL23537801 | 0.73 | OPRM1 (0.51) | CYP3A4CYP2D6USP2CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376114-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2024-11-14 | — | — | US | disclosed |
| US-20220056038-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2022-02-24 | — | — | US | disclosed |
| US-20200087313-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2020-03-19 | — | — | US | disclosed |
| EP-2736883-B1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-2736883-B1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20170137430-A1 | Nuclear Transport Modulators And Uses Thereof | KARYOPHARM THERAPEUTICS INC (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170137430-A1 | Nuclear Transport Modulators And Uses Thereof | KARYOPHARM THERAPEUTICS INC (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170137430-A1 | Nuclear Transport Modulators And Uses Thereof | KARYOPHARM THERAPEUTICS INC (US) | 2017-05-18 | — | — | US | disclosed |
| US-9428490-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428490-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428490-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2016-08-30 | — | — | US | disclosed |
| EP-2736883-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics, Inc. (US) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013019561-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| WO-2013019561-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| EP-1836211-B1 | MACROLIDES | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-7462600-B2 | Macrolides | PFIZER INC (US) | 2008-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376114-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | CYP3A4 3409/4885CYP2D6 3234/4885USP2 4509/4885 |
| US-20170137430-A1 | Nuclear Transport Modulators And Uses Thereof | XPO1, XPO5, XPOT | CYP3A4 3409/4885CYP2D6 3234/4885USP2 4509/4885 |
| US-20200087313-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | CYP3A4 3409/4885CYP2D6 3234/4885USP2 4509/4885 |
| US-20220056038-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | CYP3A4 3409/4885CYP2D6 3234/4885USP2 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.